📰 Package Leaflet News
Page 6 - Package Leaflet News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Package Leaflet. Real-time updates on events, politics, business and more.
March 31, 2022
If granted, Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in EuropeGAITHERSBURG, Md., March 31, 2022 /PRNewswire/
March 31, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
February 17, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
February 17, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
February 14, 2022
GAITHERSBURG, Md., Feb. 14, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing...
February 14, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
February 3, 2022
Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted)▼ is the first protein-based COVID-19 vaccine authorized in Great BritainNovavax and the U.K....
February 3, 2022
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...
February 3, 2022
Press release content from PR Newswire. The AP news staff was not involved in its creation.
February 3, 2022
Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted)? is the first protein-based COVID-19 vaccine authorized in Great Britain Novavax and the U.K. Vaccines Taskforce previously announced